Forest to co-develop Nabriva's BC3781; gets option to buy company--deal later terminated
Infectious disease-focused Austrian firm Nabriva Therapeutics AG has granted US specialty pharmaco Forest Laboratories Inc. rights to co-develop its Phase IIb antibacterial candidate BC3781.
- Specialty Pharmaceuticals
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.